Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of HDM1005 in adults with obstructive sleep apnea and obesity not receiving PAP therapy
CTR20263392Phase 3Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity and Overweight comparing HDM1005 with Placebo (2 arms). Primary endpoints: Percent change in body weight from baseline and Change in apnea-hypopnea index from baseline. Started Sep 2026; status: active.
02
Drugs
poterepatide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesityOverweight
Beyond the preview
Go deeper on CTR20263392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263392.